



Ibandronic acid Sandoz

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
N/0021	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/07/2022		PL	
IB/0020	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	20/10/2020	11/10/2021	SmPC, Labelling and	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



				PL	
IB/0019	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	21/07/2016	29/06/2017	SmPC, Labelling and PL	
R/0017	Renewal of the marketing authorisation.	25/02/2016	13/04/2016	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ibandronic acid Sandoz in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IAIN/0018	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	08/12/2015	13/04/2016	SmPC and PL	
IB/0016/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.z - Quality change - Active substance - Other variation	06/11/2015	n/a		
IA/0015	A.7 - Administrative change - Deletion of manufacturing sites	24/09/2015	n/a		
IB/0014	C.I.2.a - Change in the SPC, Labelling or PL of a	11/09/2015	13/04/2016	SmPC, Annex	

	generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH			II, Labelling and PL	
T/0013	Transfer of Marketing Authorisation	18/02/2015	19/03/2015	SmPC, Labelling and PL	
IA/0012	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	23/12/2014	n/a		
IB/0011	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	06/08/2014	19/03/2015	SmPC, Annex II, Labelling and PL	
IB/0008	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	06/03/2014	n/a		
IAIN/0009	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	15/01/2014	n/a		

II/0005	To add a new manufacturer of the active substance. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is supported by an ASMF	27/06/2013	n/a		
IB/0007	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	16/05/2013	03/06/2014	SmPC, Annex II, Labelling and PL	
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/02/2013	03/06/2014	PL	
IB/0004	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	20/09/2012	n/a		
IAIN/0003	C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH	30/08/2012	n/a		
IB/0002/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	08/02/2012	31/10/2012	SmPC, Annex II, Labelling and PL	

product - Implementation of change(s) for which NO new additional data are submitted by the MAH
C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH
C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH

Medicinal product no longer authorised